| Prev Close | 172.65 |
| Open | 172.72 |
| Day Low/High | 172.71 / 172.96 |
| 52 Wk Low/High | 86.00 / 172.98 |
| Volume | 4.30M |
| Avg Volume | 3.38M |
Salix Pharmaceuticals (SLXP) Stock Higher Today on Shire Takeover Talk
Salix Pharmaceuticals (SLXP) is reportedly a takeover target of Shire (SHPG) which is said to be working on a potential offer.
6 Big Pharmaceutical Companies You Don't Want in Your Portfolio
Which big pharmaceutical stocks should investors stay away from in 2015?
Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a post-market leader candidate
Watch Out: Barbarians At The Gate For Salix Pharmaceuticals (SLXP)
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Salix Announces The Promotion Of William P. Forbes, PharmD To President, Medical, R&D And Chief Development Officer
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company") today announced the promotion of William P.
Federman & Sherwood Investigates Salix Pharmaceuticals, Ltd. For Possible Violations Of Federal Securities Laws
The law firm of Federman & Sherwood has launched an investigation into Salix Pharmaceuticals, Ltd.
Salix Provides Update On Audit Committee Review
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company") today announced that the Audit Committee of Salix's Board of Directors (the "Audit Committee"), in consultation with its outside advisors and management,...
Salix Pharmaceuticals (SLXP) Shares Cross Above 200 DMA
In trading on Tuesday, shares of Salix Pharmaceuticals Ltd crossed above their 200 day moving average of $125.40, changing hands as high as $130.00 per share. Salix Pharmaceuticals Ltd shares are currently trading up about 4.7% on the day.
Salix Pharmaceuticals (SLXP) Is Today's Storm The Castle Stock
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
Pharming And Salix Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema
Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd.
Carolyn Logan To Retire As Chief Executive Officer Of Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company") today announced that Carolyn Logan has informed the Board of her decision to retire as President and Chief Executive Officer, and as a director, of the...
SLXP Investor Alert: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Salix Pharmaceuticals, Ltd. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 6, 2015
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd.
INVESTOR ALERT: Investors Of Salix Pharmaceuticals, Ltd. With Losses Of $100,000 Or More Are Encouraged To Contact Glancy Binkow & Goldberg LLP
Glancy Binkow & Goldberg LLP reminds investors of Salix Pharmaceuticals, Ltd.
Lieff Cabraser Reminds Salix Pharmaceuticals, Inc. Investors Of January 6, 2015 Lead Plaintiff Deadline In Class Litigation - SLXP
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds Salix Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Salix Pharmaceuticals, Ltd. To Contact Brower Piven Before The January 6, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Salix Pharmaceuticals Provides Updates On Wholesaler Inventory Reductions And The XIFAXAN® 550 For IBS-D Approval Timeline, And Provides Preliminary Guidance For 2015 And 2016
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company") today announced that it is working cooperatively with its principal pharmaceutical wholesalers to accelerate the reduction of wholesaler inventory levels...
SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors Of Class Action Against Salix Pharmaceuticals, Ltd. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 6, 2015
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd.
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
After a lackluster year, Cramer expects Google to deliver solid results come January when it reports earnings.
INVESTOR ALERT: Class Action Lawsuit Against Salix Pharmaceuticals, Ltd. Announced By Law Offices Of Howard G. Smith
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities of Salix ...
Salix Pharmaceuticals Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit...
Salix Pharmaceuticals Announces Plan To Augment Board Of Directors
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company") today announced that it has engaged Russell Reynolds Associates, a nationally recognized search firm, to conduct a comprehensive search to assist...
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Salix Pharmaceuticals, Ltd. To Contact Brower Piven Before The January 6, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on...
Lieff Cabraser Announces Class Action Litigation Against Salix Pharmaceuticals, Inc. - SLXP
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Salix Pharmaceuticals, Inc.
Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's "Dead Cat Bounce" Stock
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "dead cat bounce" (down big yesterday but up big today) candidate
Salix Pharmaceuticals (SLXP) Downgraded From Buy to Hold
Salix Pharmaceuticals SLXP has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+. TheStreet Ratings Team has this to say about their recommendation:
'Fast Money' Recap: When Is the Best Time to Buy Twitter Stock?
The trading panel discussed whether it would help or hurt Twitter if its CEO steps down and whether Coca-Cola has any fizz left in it.
SALIX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Salix Pharmaceuticals Ltd. Following Disclosure Of Disappointing Third Quarter Results And Resignation Of CFO
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Federman & Sherwood Investigates Salix Pharmaceuticals, Ltd. For Possible Violations Of Federal Securities Laws
The law firm of Federman & Sherwood has launched an investigation into Salix Pharmaceuticals, Ltd.